CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome
CONNECTA Therapeutics has launched a Phase IIa clinical trial for CTH120, a drug designed to modulate neuroplasticity in patients with Fragile X syndrome. The treatment targets the TrkB receptor to address the underlying neurological deficits associated with the condition.
Why it matters
This trial represents a potential breakthrough in treating neurodevelopmental disorders by focusing on the brain's ability to adapt and form connections.
CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome Sign In New user? Click Here Subscribe Sign In New user? Click Here OPINION NEWS REGIONS WORLD BUSINESS SPORTS ENTERTAINMENT LIFESTYLE THE SUNDAY TIMES SPECIAL FEATURES SPECIAL SECTIONS TMT NEWSWIRE Media OutReach Newswire PR Newswire GlobeNewswire Plentisoft FAST TIMES LEGAL ADVICE CAMPUS PRESS VIDEOS EXPATS & DIPLOMATS PHOTOS BUSINESS FORUM PODCASTS RESOURCES WEATHER MARKET OVERVIEW The Manila Times 500 EXAM RESULTS TMT DIGITAL EDITION TMT CSI TMT 127TH ANNIVERSARY QUIZZES GAMES more OPINION NEWS REGIONS WORLD BUSINESS SPORTS ENTERTAINMENT LIFESTYLE THE SUNDAY TIMES SPECIAL FEATURES SPECIAL SECTIONS TMT NEWSWIRE Media OutReach Newswire PR Newswire GlobeNewswire Plentisoft FAST TIMES LEGAL ADVICE CAMPUS PRESS VIDEOS EXPATS & DIPLOMATS PHOTOS BUSINESS FORUM PODCASTS RESOURCES WEATHER MARKET OVERVIEW The Manila Times 500 EXAM RESULTS TMT DIGITAL EDITION TMT CSI TMT 127TH ANNIVERSARY QUIZZES GAMES OPINION NEWS REGIONS WORLD BUSINESS SPORTS ENTERTAINMENT LIFESTYLE THE SUNDAY TIMES SPECIAL FEATURES SPECIAL SECTIONS TMT NEWSWIRE Media OutReach Newswire PR Newswire GlobeNewswire Plentisoft FAST TIMES LEGAL ADVICE CAMPUS PRESS VIDEOS EXPATS & DIPLOMATS PHOTOS BUSINESS FORUM PODCASTS RESOURCES WEATHER MARKET OVERVIEW The Manila Times 500 EXAM RESULTS TMT DIGITAL EDITION TMT CSI TMT 127TH ANNIVERSARY QUIZZES GAMES TMT Newswire GlobeNewswire CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome By GlobeNewswire June 10, 2026 Resize Small Medium Large
The article is a straightforward report on a clinical trial announcement.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in